Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HS-10360 in Healthy Subjects
NCT04986436Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing HS-10360 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events, Moderate or Severe Treatment-Emergent Adverse Events and 4 more. Status: unknown.
02
Drugs
HS-10360
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04986436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986436.